-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the steady advancement of medical reform and the opening of capital markets, domestic pharmaceutical companies have accelerated their innovation and transformation.
Data shows that the R&D investment of listed biomedical companies is continuously expanding
.
In 2020, the R&D expenditure of listed biomedical companies in China will be 11.
534 billion yuan, a year-on-year increase of 37.
10%
.
By the first half of 2021, the R&D expenditures of listed biomedical companies in China have reached 6.
978 billion yuan.
The annual R&D expenditures are expected to continue to grow.
With high R&D investment, the transformation of research results of pharmaceutical companies is also accelerating
.
On the whole, the innovative drug industry has ushered in rapid development, with the number of new drugs approved and the proportion of clinical trial applications reaching new highs year by year
.
At present, the domestic innovative drug industry has entered a state where a hundred flowers bloom and a hundred schools of thought are contending.
Some tracks such as PD-1 and small molecule targeted drugs have become very crowded.
ADC, double antibodies, RNAi, gene editing, mRNA and other innovative new Technology is regarded as the outlet for pharmaceutical companies to compete next
.
It is worth mentioning that the pharmaceutical industry involves many links.
In addition to clinical trials, it also includes production and commercialization.
With the successive launch of innovative drug products, corporate competition will also focus on subsequent production and commercialization
.
On November 19 this year, the "Guiding Principles for Clinical Research and Development of Anti-tumor Drugs Oriented by Clinical Value" issued by CDE was officially implemented, which means that China's innovative drug research and development has entered a new era of clinical value-oriented and patient-centric.
.
In this context, the industry generally believes that it will become a trend for pharmaceutical companies to walk on multiple legs
.
Southwest Securities analysis pointed out that at present, China has shifted from a relationship and marketing advantage orientation to a product and price advantage orientation in the new drug access model.
The guiding principles are implemented and the clinical value-oriented new drug research and development concept will promote drugs.
Innovation takes it to the next level
.
At the same time, innovative drugs are emerging from an era where both "quantity" and "quality" are rising, and homogeneous innovation needs to be broken
.
The agency believes that China has completed the initial quantitative change process of innovative drugs, and its pharmaceutical innovation capabilities have gradually gained international recognition.
More and more innovative drugs developed by Chinese companies are going international
.
However, China's R&D foundation is relatively weak, and innovation and research research focuses on following up hot frontiers, with serious homogeneity
.
It is expected that the development of new me too drugs may be severely involved in the next 3-5 years, and the me too strategy will quickly fail.
Only innovative drugs with differentiated and high-tech barriers can come to the fore and cause a wave of growth
.
In response to the problem of weak research and development, many local innovative drug companies are actively seeking cooperation, and in recent years, the trend has gradually shifted from seeking cooperation with multinational pharmaceutical companies to strong cooperation between local pharmaceutical companies, such as Hengrui Pharmaceuticals, Wanchun Pharmaceuticals, and Cornerstone In the pharmaceutical industry, Chia Tai Tianqing and Yiyi Biological, Kangfang Pharmaceutical, Tianjing Biological and Jichuan Pharmaceutical, etc.
have cooperated around clinical drugs to accelerate the research and development process
.
In addition, some local pharmaceutical companies that have R&D capabilities but lack commercialization capabilities are also adopting the License-out model to push their products to a wider overseas market
.
Since 2021, companies including Baekje and Cinda have been "going out" with their strengths
.
Among them, Rongchang Biological and Seattle Genes reached a cooperation on the development and commercialization of its new ADC drug vedicitumumab.
The transaction amounted to US$2.
6 billion; Cinda and Novartis reached a global commercialization of tislelizumab.
Cooperation, the total transaction amount is as high as 2.
2 billion US dollars
.
Data shows that the R&D investment of listed biomedical companies is continuously expanding
.
In 2020, the R&D expenditure of listed biomedical companies in China will be 11.
534 billion yuan, a year-on-year increase of 37.
10%
.
By the first half of 2021, the R&D expenditures of listed biomedical companies in China have reached 6.
978 billion yuan.
The annual R&D expenditures are expected to continue to grow.
With high R&D investment, the transformation of research results of pharmaceutical companies is also accelerating
.
On the whole, the innovative drug industry has ushered in rapid development, with the number of new drugs approved and the proportion of clinical trial applications reaching new highs year by year
.
At present, the domestic innovative drug industry has entered a state where a hundred flowers bloom and a hundred schools of thought are contending.
Some tracks such as PD-1 and small molecule targeted drugs have become very crowded.
ADC, double antibodies, RNAi, gene editing, mRNA and other innovative new Technology is regarded as the outlet for pharmaceutical companies to compete next
.
It is worth mentioning that the pharmaceutical industry involves many links.
In addition to clinical trials, it also includes production and commercialization.
With the successive launch of innovative drug products, corporate competition will also focus on subsequent production and commercialization
.
On November 19 this year, the "Guiding Principles for Clinical Research and Development of Anti-tumor Drugs Oriented by Clinical Value" issued by CDE was officially implemented, which means that China's innovative drug research and development has entered a new era of clinical value-oriented and patient-centric.
.
In this context, the industry generally believes that it will become a trend for pharmaceutical companies to walk on multiple legs
.
Southwest Securities analysis pointed out that at present, China has shifted from a relationship and marketing advantage orientation to a product and price advantage orientation in the new drug access model.
The guiding principles are implemented and the clinical value-oriented new drug research and development concept will promote drugs.
Innovation takes it to the next level
.
At the same time, innovative drugs are emerging from an era where both "quantity" and "quality" are rising, and homogeneous innovation needs to be broken
.
The agency believes that China has completed the initial quantitative change process of innovative drugs, and its pharmaceutical innovation capabilities have gradually gained international recognition.
More and more innovative drugs developed by Chinese companies are going international
.
However, China's R&D foundation is relatively weak, and innovation and research research focuses on following up hot frontiers, with serious homogeneity
.
It is expected that the development of new me too drugs may be severely involved in the next 3-5 years, and the me too strategy will quickly fail.
Only innovative drugs with differentiated and high-tech barriers can come to the fore and cause a wave of growth
.
In response to the problem of weak research and development, many local innovative drug companies are actively seeking cooperation, and in recent years, the trend has gradually shifted from seeking cooperation with multinational pharmaceutical companies to strong cooperation between local pharmaceutical companies, such as Hengrui Pharmaceuticals, Wanchun Pharmaceuticals, and Cornerstone In the pharmaceutical industry, Chia Tai Tianqing and Yiyi Biological, Kangfang Pharmaceutical, Tianjing Biological and Jichuan Pharmaceutical, etc.
have cooperated around clinical drugs to accelerate the research and development process
.
In addition, some local pharmaceutical companies that have R&D capabilities but lack commercialization capabilities are also adopting the License-out model to push their products to a wider overseas market
.
Since 2021, companies including Baekje and Cinda have been "going out" with their strengths
.
Among them, Rongchang Biological and Seattle Genes reached a cooperation on the development and commercialization of its new ADC drug vedicitumumab.
The transaction amounted to US$2.
6 billion; Cinda and Novartis reached a global commercialization of tislelizumab.
Cooperation, the total transaction amount is as high as 2.
2 billion US dollars
.
